Protection assessments indicated that gastrointestinal adverse situations, primarily nausea and diarrhea, had been dose-dependent but frequently gentle and transient. These conclusions established the therapeutic window and knowledgeable dose selection for subsequent Period 3 trials.Continued refinement of formulation and dosing approaches may even